Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

IsraelCompletedPHASE3

Conditions

Muscular Dystrophy, Duchenne

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Arkansas Children's Hospital, Little Rock, Arkansas, United States

  • Children's Hospital of Los Angeles, Los Angeles, California, United States

  • UC Davis, Sacramento, California, United States

  • Nemours Children's Hospital, Orlando, Florida, United States

  • Rare Disease Research, LLC, Atlanta, Georgia, United States

  • Rush University Children's Hospital, Chicago, Illinois, United States

  • University of Iowa Children's Hospital, Iowa City, Iowa, United States

  • University of Kansas Medical Center, Fairway, Kansas, United States

  • Kennedy Krieger Institute, Baltimore, Maryland, United States

  • Johns Hopkins School of Medicine, Baltimore, Maryland, United States

  • Boston Children's Hospital, Boston, Massachusetts, United States

  • University of Michigan, Ann Arbor, Michigan, United States

  • University of Minnesota, Minneapolis, Minnesota, United States

  • Las Vegas Clinic, Las Vegas, Nevada, United States

  • Cincinnati Children's Hospital, Cincinnati, Ohio, United States

  • MetroHealth Medical Center, Cleveland, Ohio, United States

  • Shriners Hospitals for Children, Portland, Oregon, United States

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

  • Cook Children's Medical Center, Fort Worth, Texas, United States

  • University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

  • University of Utah, Salt Lake City, Utah, United States

  • Children's Hospital of the King's Daughters, Norfolk, Virginia, United States

  • Children's Hospital of Richmond at VCU, Richmond, Virginia, United States

  • The Children's Hospital at Westmead, Westmead, New South Wales, Australia

  • Children's Health Queensland Children's Hospital and Health Service, South Brisbane, Queensland, Australia

  • Royal Children's Hospital, Parkville, Victoria, Australia

  • Alberta Children's Hospital, Calgary, Alberta, Canada

  • London Health Sciences Centre - Children's Hospital, London, Ontario, Canada

  • Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

  • CHU Sainte-Justine, Montreal, Quebec, Canada

  • University of Hamburg, Hamburg, Germany

  • University of Munich, Munich, Germany

  • Children's University Hospital, Dublin, Ireland

  • Hadassah Medical Center, Jerusalem, Israel

  • Queen Silvia Children's Hospital, Gothenburg, Sweden

  • Bristol Children's Hospital, Bristol, United Kingdom

  • Evelina Children's Hospital, London, United Kingdom

  • Great Ormond Street Hospital (GOSH), London, United Kingdom

  • Royal Manchester Children's Hospital, Manchester, United Kingdom

Study leads
  • Joanne M Donovan, Chief Medical Officer, MD, PhD

    Study Chair

    Catabasis Pharmaceuticals